DRG Epidemiology's coverage of neuromyelitis optica syndrome disorder comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the incidence and prevalence of neuromyelitis optica syndrome disorder for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's neuromyelitis optica syndrome disorder forecast will answer the following questions:
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts 2 neuromyelitis optica syndrome disorder patient populations, as follows: